Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05621707 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

Study acronym: RICE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 19, 2024 to Oct 2026v2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study completion date: Nov 19, 2026 to Oct 2026
    • Start date changed from estimate of Nov 20, 2022 to Nov 2, 2022
    • Secondary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.
Trial Details
NCT Number NCT05621707
Lead Sponsor Shanghai Chest Hospital
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
Related terms Esophageal Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov